Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · IEX Real-Time Price · USD
7.63
-0.50 (-6.15%)
At close: Jul 2, 2024, 4:00 PM
8.01
+0.38 (4.98%)
After-hours: Jul 2, 2024, 7:38 PM EDT
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
150
Market Cap
608.52M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 33.19M | 14.38M | 76.41% |
Dec 31, 2021 | 18.82M | 3.41M | 22.16% |
Dec 31, 2020 | 15.40M | -5.09M | -24.83% |
Dec 31, 2019 | 20.49M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 379.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetIQ | 1.12B |
Phibro Animal Health | 999.56M |
InnovAge Holding | 741.33M |
GeneDx Holdings | 221.85M |
Evolus | 219.70M |
Standard BioTools | 126.76M |
Arcturus Therapeutics Holdings | 124.53M |
Sage Therapeutics | 91.06M |
SRRK News
- 8 days ago - Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal - Business Wire
- 14 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting - Business Wire
- 5 weeks ago - Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 5 weeks ago - Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity - Business Wire
- 6 weeks ago - Scholar Rock to Participate in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Scholar Rock to Host Investor Day on May 22, 2024 - Business Wire
- 2 months ago - Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress - Business Wire